{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6"},{"groupId":"OG001","value":"45.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"374"},{"groupId":"OG001","value":"362"}],"units":"Participants"}],"description":"A Clinical Benefit (CB) responder is defined as a patient having a best overall response of CR, PR or SD (stable disease) \\>=24 weeks. The Clinical Benefit Rate is the percentage of patients with CB.","groups":[{"description":"Fulvestrant 250 mg Intramuscular Injection every 28 days","id":"OG000","title":"Fulvestrant 250 mg"},{"description":"Fulvestrant 500 mg Intramuscular Injection every 28 days plus 500 mg on day 14","id":"OG001","title":"Fulvestrant 500 mg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Clinical Benefit from the sequence of RECIST scan data for study duration (48 months) . RECIST (Response Evaluation Criteria in Solid Tumours) scans were performed every 12 weeks (+/- 2 weeks) from randomisation for study duration (48 months)","title":"Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"Percentage of patients"}